A new clutch of biotech blue-chip­pers joins Ob­sid­i­an's quest to craft next-gen drugs with an 'on' switch

The brain­child of se­r­i­al biotech en­tre­pre­neur Michael Gilman, Ob­sid­i­an is hop­ing to bring some­thing new to the par­ty with “on-switch” tech­nol­o­gy for a range of po­ten­tial drug ap­pli­ca­tions. Ob­sid­i­an now has a new trea­sure chest to play with — and an IPO feels on­ly a fin­ger­tip away.

Ob­sid­i­an closed a $115 mil­lion Se­ries B with a new group of biotech blue-blood in­vestors join­ing the Cam­bridge, MA biotech’s al­ready stacked syn­di­cate of back­ers, the com­pa­ny said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER